Targets for immunotherapy in early-stage breast cancer

A new molecular analysis tool has been used to detect the level of an important target for immunotherapy in early-stage breast cancers, researchers report. The diagnostic test, using RNAScope, measures the amount of PD-L1 mRNA in cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials.